- Home
- CHY vs AVBP Comparison
CHY vs AVBP Comparison
Compare CHY & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- AVBP
- Stock Information
- Founded
- CHY 2003
- AVBP 2021
- Country
- CHY United States
- AVBP United States
- Employees
- CHY N/A
- AVBP N/A
- Industry
- CHY Investment Managers
- AVBP
- Sector
- CHY Finance
- AVBP
- Exchange
- CHY Nasdaq
- AVBP NYSE
- Market Cap
- CHY 792.1M
- AVBP 705.8M
- IPO Year
- CHY N/A
- AVBP 2024
- Fundamental
- Price
- CHY $10.39
- AVBP $21.41
- Analyst Decision
- CHY
- AVBP Strong Buy
- Analyst Count
- CHY 0
- AVBP 7
- Target Price
- CHY N/A
- AVBP $39.29
- AVG Volume (30 Days)
- CHY 128.3K
- AVBP 234.7K
- Earning Date
- CHY 01-01-0001
- AVBP 05-12-2025
- Dividend Yield
- CHY 10.11%
- AVBP N/A
- EPS Growth
- CHY N/A
- AVBP N/A
- EPS
- CHY N/A
- AVBP N/A
- Revenue
- CHY N/A
- AVBP N/A
- Revenue This Year
- CHY N/A
- AVBP $63.13
- Revenue Next Year
- CHY N/A
- AVBP N/A
- P/E Ratio
- CHY N/A
- AVBP N/A
- Revenue Growth
- CHY N/A
- AVBP N/A
- 52 Week Low
- CHY $9.97
- AVBP $15.47
- 52 Week High
- CHY $12.16
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- CHY 54.62
- AVBP 61.57
- Support Level
- CHY $10.20
- AVBP $19.80
- Resistance Level
- CHY $10.43
- AVBP $20.86
- Average True Range (ATR)
- CHY 0.12
- AVBP 1.05
- MACD
- CHY -0.02
- AVBP 0.16
- Stochastic Oscillator
- CHY 52.70
- AVBP 99.36
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.